不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
原发性中枢神经系统结外 NK/T 细胞淋巴瘤经手术和化疗联合信迪利单抗成功治疗：一例病例报告及文献复习
英文原题：Successful Treatment of Primary CNS Extranodal NK/T-Cell Lymphoma with Surgery and Chemotherapy Combined with Sintilimab: A Case Report and Literature Review.
查看英文原题
Successful Treatment of Primary CNS Extranodal NK/T-Cell Lymphoma with Surgery and Chemotherapy Combined with Sintilimab: A Case Report and Literature Review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
原发性中枢神经系统结外NK/T细胞淋巴瘤（PCNS ENK/TCL）是一种极为罕见的淋巴瘤。英文文献中仅报道了23例PCNS ENK/TCL。由于该淋巴瘤罕见，尚未确定有效的治疗策略。通常，该类型淋巴瘤采用手术、鞘内化疗和术后放化疗。预后较差。本文报道一例50岁免疫功能正常中国女性原发性脑NK/T细胞淋巴瘤，并复习文献。患者接受颅内肿瘤切除术，随后接受PD1单克隆抗体（信迪利单抗）联合化疗。患者确诊后生存15个月。这是首例接受手术和化疗联合免疫治疗的PCNS ENK/TCL报告，提示了一种有效的PCNS ENK/TCL治疗方案。
展开英文摘要原文
Primary central nervous system extranodal natural killer/T-cell lymphoma (PCNS ENK/TCL) is an extremely rare lymphoma. Only 23 cases of PCNS ENK/TCL have been reported in the English literature. Due to the rarity of this lymphoma, an effective therapeutic strategy has not been defined. Generally, this type of lymphoma is treated with surgery, intrathecal chemotherapy, and postoperative chemoradiation therapy. The prognosis is poor.
Herein, we present a case of primary brain NK/T cell lymphoma in a 50-year-old immunocompetent Chinese female and review the literature. The patient underwent intracranial tumor resection and was subsequently treated with a PD1 monoclonal antibody (Sintilimab) combined with chemotherapy. The patient survived 15 months after diagnosis. This is the first report of PCNS ENK/TCL treated with surgery and chemotherapy combined with immunotherapy and suggests an effective treatment regimen for PCNS ENK/TCL.
论文信息
- 作者
- Qin L、Li Y、He Y、Zeng R、Pan T、Zuo Y、Xiao L、Zhou H
- 第一作者单位
- Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People's Republic of China.China
- 通讯作者单位
- Department of Lymphoma and Hematology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, People's Republic of China.China
- 文献类型
- 病例报告
- 期刊
- OncoTargets and therapy2022
- 原文标识
- PubMed 35023929 · DOI 10.2147/OTT.S343400
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →